Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non–Small-Cell Lung Cancer
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (2) , e116-e117
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab TreatmentJournal of Thoracic Oncology, 2019
- Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specificPLOS Pathogens, 2018
- Foundations of Immunometabolism and Implications for Metabolic Health and DiseaseImmunity, 2017
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunityNature, 2017
- Pseudoprogression and Immune-Related Response in Solid TumorsJournal of Clinical Oncology, 2015
- Clinical approach to endogenous lipoid pneumoniaThe Clinical Respiratory Journal, 2014
- Lipoid pneumonia: an overviewExpert Review of Respiratory Medicine, 2010
- Radiological and Clinical Findings in Acute and Chronic Exogenous Lipoid PneumoniaJournal of Thoracic Imaging, 2003